January 2020- Volume 16, Issue 1

In this Issue

Contract Services

Drugging the undruggable

Drugging the undruggable

Cresset Discovery Services contracted by PhoreMost to work on oncology protein target

Dose CMO industry performing strongly

Dose CMO industry performing strongly

This despite challenges of increasingly complex drug production, says GlobalData

Business & Government Policy

Patent Docs: More on patent-ineligibility from the Federal Circuit

Patent Docs: More on patent-ineligibility from the Federal Circuit

The Federal Circuit continuse to expand the scope of patent-ineligible invention in its recent iNo Therapeutics LLC v. Praxair Distribution Inc. decision, relying on Justice Breyer's exhortation, in his Mayo Collaborative Serv. Inc. v. Prometheus Laboratories opinion

End of the road

End of the road

Illumina and Pacific Biosciences announce termination of merger agreement

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Expedeon and Abcam close transaction

Expedeon and Abcam close transaction

With deal sealed, Expedeon changes name and shifts to DNA manufacturing and enzymes for diagnostics

Discovery

Onward and upward

Onward and upward

Three companies will enter 2020 with support to launch new growth

Models for seeing things more clearly

Models for seeing things more clearly

Two new cell models for ocular drug discovery could reduce the need for animal testing

Streamlining CRISPR gene-editing workflows

Streamlining CRISPR gene-editing workflows

Individual sgRNA and library collections expand Edit-R gene-editing platform

Making waves with macrophages

Making waves with macrophages

NTU Singapore scientists discover new key to promote insulin production in pre-diabetes patients

Collaboration “DUBbed” a success

Collaboration “DUBbed” a success

Mission and AbbVie deal reaches milestone as partnership continues

Commentary

Out of order: For the better

Out of order: For the better

Science is elusive and ever shifting, refusing to come into focus, and that is both its curse and its blessing

Case study: Managing informatics challenges across distributed drug discovery projects

Case study: Managing informatics challenges across distributed drug discovery projects

Collaboration between drug discovery groups from different sites, organizations and companies has become much more common, and distributing research can have profound advantages even as managing the process poses unique challenges

Research & Development

Aggravating atherosclerosis

Aggravating atherosclerosis

Study of T cells sheds light on cardiovascular events

Open Targets finds differences in immune disease DNA

Open Targets finds differences in immune disease DNA

With strong financial backing from Open Targets, a battery of scientists is working to identify specific variations in DNA that correspond with different immune diseases

Akoya finds $50M more in financing

Akoya finds $50M more in financing

Funding will support continued commercialization of Akoya’s spatial biology platforms

Oral therapy for hemophilia

Oral therapy for hemophilia

Bayer enters into collaboration with Children’s Hospital of Philadelphia on novel small-molecule drugs

Preclinical

Targeting tough tumors

Targeting tough tumors

Femtogenix payload platform has favorable toxicity profile

A model replacement?

A model replacement?

Heart-on-a-Chip technology predicts preclinical systolic, diastolic in-vivo observations for cardiac drug candidate

Knowing the score

Knowing the score

New application helps authors, publishers address heightened reproducibility and transparency standards

Immunic presents data on IMU-856 at Crohn’s and colitis conference

Immunic presents data on IMU-856 at Crohn’s and colitis conference

IMU-856 might address a root cause of inflammatory bowel disease without impairing immune system

Meeting a new mechanism

Meeting a new mechanism

Samumed publishes unique mechanism of action for SM08502

Clinical Trials

Resistance to Alzheimer’s is not futile

Resistance to Alzheimer’s is not futile

Troriluzole successfully advances past interim futility analysis in pivotal Phase 2/3 study

Triple combination study shows promise

Triple combination study shows promise

BioLineRx’s combination regimen leads to improved disease control in pancreatic cancer

Antibody vs. Alzheimer’s disease

Antibody vs. Alzheimer’s disease

Alector announces Phase 1 data on AL002 at 12th annual CTAD meeting

ADVM-022 success is no OPTICal illusion

ADVM-022 success is no OPTICal illusion

Adverum’s wet AMD candidate helps maintain vision in Phase 1 trial

Phase 3 on the horizon

Phase 3 on the horizon

Oramed's oral insulin candidate shows efficacy in Phase 2b diabetes trial

Diagnostics

Stepping up against sepsis

Stepping up against sepsis

Companies ink agreement to develop rapid, point-of-care solution for diagnosing bloodstream infections

Cologuard mechanism tested for liver cancer

Cologuard mechanism tested for liver cancer

Test that has proven useful for non-invasive colorectal cancer screening leads to new possibilities


Duo for diagnostics

Duo for diagnostics

Startup company Breakthrough Diagnostics performs clinical testing of LymPro test for Alzheimer’s disease

Special Reports

Feature

Editor's Focus

Editor’s Focus: Double helix, double bind

Editor’s Focus: Double helix, double bind

Of all the areas where 'just because you can doesn't mean you should' ought to be a leading tenet, genomics is at the top of the list. The promise of gene editing must be partnered with caution regarding the ways it could be mishandled; we need to decide now which lines shouldn't be crossed, rather than backtracking after someone steps over them.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 16 • Issue 10 • November 2020

November 2020

November 2020 Issue